60 Degrees Pharmaceuticals Finds Babesia Infection in 24% of Patients with Chronic Fatigue, Validates B-FREE Study.

60 Degrees Pharmaceuticals announced that Babesia infection was detected in 24% of patients with chronic fatigue in a peer-reviewed study at NC State. The findings support the theory that Babesia infection may prolong recovery times in patients with chronic fatigue and validate the continuation of the B-FREE Study to evaluate the efficacy and safety of ARAKODA (tafenoquine) for treating chronic babesiosis. The study was conducted by researchers at North Carolina State University and published in Pathogens.